Tiwari A, Paithane U, Friedlein J, Tashiro K, Saulnier O, Barbosa K
bioRxiv. 2025; .
PMID: 40027648
PMC: 11870553.
DOI: 10.1101/2025.02.17.638454.
Kent A, Yee Mon K, Hutchins Z, Putzel G, Zhigarev D, Grier A
Nat Immunol. 2025; 26(1):53-67.
PMID: 39747433
DOI: 10.1038/s41590-024-02028-z.
Pundlik S, Barik A, Venkateshvaran A, Sahoo S, Jaysingh M, Math R
Elife. 2024; 13.
PMID: 39196610
PMC: 11357351.
DOI: 10.7554/eLife.95229.
Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L
Signal Transduct Target Ther. 2024; 9(1):205.
PMID: 39164274
PMC: 11336233.
DOI: 10.1038/s41392-024-01907-z.
Ueno T, Otani S, Date Y, Katsuma Y, Nagayoshi Y, Ito T
Cancer Sci. 2024; 115(9):2961-2971.
PMID: 38924236
PMC: 11462974.
DOI: 10.1111/cas.16255.
FAK loss reduces BRAF-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation.
Gao C, Ge H, Kuan S, Cai C, Lu X, Esni F
Elife. 2024; 13.
PMID: 38921956
PMC: 11208045.
DOI: 10.7554/eLife.94605.
FOXK2 amplification promotes breast cancer development and chemoresistance.
Yu Y, Cao W, Cheng F, Shi Z, Han L, Yi J
Cancer Lett. 2024; 597:217074.
PMID: 38901667
PMC: 11290987.
DOI: 10.1016/j.canlet.2024.217074.
Synergistic epistasis among cancer drivers can rescue early tumors from the accumulation of deleterious passengers.
Alejandre C, Calle-Espinosa J, Iranzo J
PLoS Comput Biol. 2024; 20(4):e1012081.
PMID: 38687804
PMC: 11087069.
DOI: 10.1371/journal.pcbi.1012081.
Ginsenoside Rg3 decreases breast cancer stem-like phenotypes through impairing MYC mRNA stability.
Ning J, Zhang Z, Zhang J, Liu Y, Li G, Wang A
Am J Cancer Res. 2024; 14(2):601-615.
PMID: 38455405
PMC: 10915333.
Cellular senescence: Neither irreversible nor reversible.
Reimann M, Lee S, Schmitt C
J Exp Med. 2024; 221(4).
PMID: 38385946
PMC: 10883852.
DOI: 10.1084/jem.20232136.
Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.
Hamilton G, Stickler S, Rath B
Curr Cancer Drug Targets. 2024; 24(9):930-940.
PMID: 38275056
DOI: 10.2174/0115680096272757231211113206.
Unraveling MYC's Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance.
Doha Z, Sears R
Pathophysiology. 2023; 30(3):400-419.
PMID: 37755397
PMC: 10537413.
DOI: 10.3390/pathophysiology30030031.
Comparison of Tumour-Specific Phenotypes in Human Primary and Expandable Pancreatic Cancer Cell Lines.
Guo F, Kan K, Ruckert F, Ruckert W, Li L, Eberhard J
Int J Mol Sci. 2023; 24(17).
PMID: 37686338
PMC: 10488093.
DOI: 10.3390/ijms241713530.
Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems.
Abdul-Aziz A, Devine R, Lyberger J, Chang H, Kovacs A, Lerma J
Cells. 2023; 12(16).
PMID: 37626855
PMC: 10453346.
DOI: 10.3390/cells12162045.
RUNX3 inactivates oncogenic MYC through disruption of MYC/MAX complex and subsequent recruitment of GSK3β-FBXW7 cascade.
Oei V, Chuang L, Matsuo J, Srivastava S, Teh M, Ito Y
Commun Biol. 2023; 6(1):689.
PMID: 37400551
PMC: 10317990.
DOI: 10.1038/s42003-023-05037-0.
Zebrafish imaging reveals hidden oncogenic-normal cell communication during primary tumorigenesis.
Haraoka Y, Miyake M, Ishitani T
Cell Struct Funct. 2023; 48(1):113-121.
PMID: 37164759
PMC: 10721949.
DOI: 10.1247/csf.23026.
MYC determines lineage commitment in KRAS-driven primary liver cancer development.
DArtista L, Moschopoulou A, Barozzi I, Craig A, Seehawer M, Herrmann L
J Hepatol. 2023; 79(1):141-149.
PMID: 36906109
PMC: 10330789.
DOI: 10.1016/j.jhep.2023.02.039.
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Smith B, Deutzmann A, Correa K, Delaveris C, Dhanasekaran R, Dove C
Proc Natl Acad Sci U S A. 2023; 120(11):e2215376120.
PMID: 36897988
PMC: 10089186.
DOI: 10.1073/pnas.2215376120.
The RUNX Family Defines Trk Phenotype and Aggressiveness of Human Neuroblastoma through Regulation of p53 and MYCN.
Ando K, Nakagawara A
Cells. 2023; 12(4).
PMID: 36831211
PMC: 9954111.
DOI: 10.3390/cells12040544.
An in vitro carcinogenesis model for cervical cancer harboring episomal form of HPV16.
Wongjampa W, Nakahara T, Tanaka K, Yugawa T, Ekalaksananan T, Kleebkaow P
PLoS One. 2023; 18(2):e0281069.
PMID: 36763589
PMC: 9916646.
DOI: 10.1371/journal.pone.0281069.